[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019006940A - Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar. - Google Patents

Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.

Info

Publication number
MX2019006940A
MX2019006940A MX2019006940A MX2019006940A MX2019006940A MX 2019006940 A MX2019006940 A MX 2019006940A MX 2019006940 A MX2019006940 A MX 2019006940A MX 2019006940 A MX2019006940 A MX 2019006940A MX 2019006940 A MX2019006940 A MX 2019006940A
Authority
MX
Mexico
Prior art keywords
bipolar disorder
alleviation
prevention
treatment
carbamate compounds
Prior art date
Application number
MX2019006940A
Other languages
English (en)
Inventor
Jin Shin Yu
Myoung Han Sei
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2019006940A publication Critical patent/MX2019006940A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona al uso para el propósito de prevenir, aliviar o tratar el trastorno bipolar al administrar una composición farmacéutica que comprende un compuesto de carbamato de la siguiente fórmula química 1.
MX2019006940A 2016-12-14 2017-12-14 Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar. MX2019006940A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
MX2019006940A true MX2019006940A (es) 2019-09-06

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006940A MX2019006940A (es) 2016-12-14 2017-12-14 Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.

Country Status (13)

Country Link
US (1) US11571410B2 (es)
EP (1) EP3556366A4 (es)
JP (1) JP7208139B2 (es)
KR (1) KR102635938B1 (es)
CN (1) CN110290788A (es)
AU (1) AU2017374458B2 (es)
BR (1) BR112019011930A2 (es)
CA (1) CA3046297A1 (es)
CL (1) CL2019001618A1 (es)
IL (1) IL267195B2 (es)
MX (1) MX2019006940A (es)
WO (1) WO2018111008A1 (es)
ZA (1) ZA201903747B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021005193A2 (pt) * 2018-09-21 2021-06-08 Sk Biopharmaceuticals Co., Ltd. medicamento e combinação para a prevenção, alívio ou tratamento de transtorno de estresse agudo ou transtorno de estresse pós-traumático, e, medicamento para a prevenção, alívio ou tratamento de sintoma de transtorno de estresse pós-traumático
JP7417595B2 (ja) * 2018-09-21 2024-01-18 エスケー バイオファーマスティカルズ カンパニー リミテッド てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用
EP4062906A4 (en) * 2019-11-22 2024-01-03 SK Biopharmaceuticals Co., Ltd. ORAL PHARMACEUTICAL COMPOSITION COMPRISING A CARBAMATE COMPOUND AND METHOD FOR PREPARING THIS COMPOSITION

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1003505B1 (en) * 1997-08-14 2004-03-24 F. Hoffmann-La Roche Ag Heterocyclic vinylethers against neurological disorders
CZ2004266A3 (cs) * 2000-07-21 2005-02-16 Teva Pharmaceutical Industries, Ltd. Použití derivátů amidů kyseliny valproové a kyseliny 2-valproenové pro léčbu mánie při bipolární poruše
BR0207644A (pt) * 2001-02-27 2004-03-09 Ortho Mcneil Pharm Inc Compostos de carbamato para uso na prevenção ou no tratamento de distúrbio bipolar
EP1368021B1 (en) 2001-02-27 2007-11-14 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
EA200970435A1 (ru) 2006-10-31 2009-10-30 Янссен Фармацевтика, Н. В. Лечение общих расстройств развития
EP2445890B1 (en) 2009-06-22 2015-05-06 SK Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
PL3180329T3 (pl) 2014-08-15 2020-08-24 Janssen Pharmaceuticals, Inc. Triazole jako inhibitory receptora NR2B

Also Published As

Publication number Publication date
AU2017374458A1 (en) 2019-07-04
CN110290788A (zh) 2019-09-27
RU2019121913A3 (es) 2021-04-21
RU2019121913A (ru) 2021-01-15
IL267195A (es) 2019-07-31
KR20190087572A (ko) 2019-07-24
JP2020502106A (ja) 2020-01-23
US20190314337A1 (en) 2019-10-17
IL267195B1 (en) 2024-01-01
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
WO2018111008A1 (ko) 2018-06-21
CL2019001618A1 (es) 2019-08-23
JP7208139B2 (ja) 2023-01-18
AU2017374458B2 (en) 2023-03-02
KR102635938B1 (ko) 2024-02-13
ZA201903747B (en) 2021-01-27
EP3556366A1 (en) 2019-10-23
CA3046297A1 (en) 2018-06-21
BR112019011930A2 (pt) 2019-10-29
US11571410B2 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MY197698A (en) Oxysterols and methods of use thereof
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
NZ746825A (en) Oxysterols and methods of use thereof
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
MX2021010700A (es) Compuestos utiles en la terapia del vih.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
MX2019012522A (es) Compuestos y metodos terapeuticos.
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
SG11201803867TA (en) Sodium channel blocker
MX2019006941A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el sindrome de temblor.